LIMK1 and cancer: This analysis revealed that neuroblastoma, rhabdomyosarcoma and kidney cancer cells were significantly sensitive to both LIMK inhibitors, with 6 additional cancer types being sensitive to either inhibitor and trending towards sensitivity to the other (e.g. Ewing's sarcoma, osteosarcoma and additional soft tissue cancer cell lines).